FibroBiologics FBLG 深 沪
等待开盘 08-14 09:30:00 美东时间
1.15
+0.040
+3.60%
华盛通- 最 高1.2792
- 今 开1.11
- 成交量 38.59万股
- 最 低 1.1063
- 昨 收 1.11
- 总市值 765.69万
- 52周最高 12.80
- 市盈率 静 --
- 换手率 5.80%
- 52周最低 0.6201
- 委 比 0.59%
- 总股本 665.82万
- 历史最高 1100.00
- 量 比 1.42
- 振 幅 15.58%
- 历史最低 1.1063
- 每 手 1
- 风险率 3.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FibroBiologics Says USPTO Issues US Patent Entitled Methods And Compositions For Treatment Of Type 1 Diabetes Using Fibroblasts In Facilitation Of Islet Engraftment
Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on ...
08-11 20:39
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
FibroBiologics 2026年第二季度财报：净亏损410万美元，CYWC628进入临床
FibroBiologics（FBLG）2026年第二季度净亏损约410万美元，研发费用降至170万美元，期末现金约350万美元；CYWC628已启动患者给药，预计下半年公布中期结果。
08-05 06:13
Snap To Rally More Than 217%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham cut the price target for ON Semiconductor Corp (NASDAQ:ON) from $130 to $116. Needham analyst N. Quinn...
08-04 19:52
HC Wainwright & Co. Maintains Buy on FibroBiologics, Lowers Price Target to $6
HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Buy and lowers the price target from $8 to $6.
08-04 18:15
FibroBiologics shares are trading higher after the company reported better-than-expected Q2 EPS results.
FibroBiologics shares are trading higher after the company reported better-than-expected Q2 EPS results.
08-04 02:02
FibroBiologics, Inc. - Common Stock Q2 EPS $(0.66) Beats $(0.72) Estimate
FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.72) by 8.33 percent. This is a 72.5 percent increase over losses of $(2.40) per share from the same period last year.
08-01 05:38
FibroBiologics Faces Nasdaq Delisting, Appeals Planned
FibroBiologics, Inc. ( ($FBLG) ) just unveiled an announcement. On July 22, 202...
07-25 04:37
FibroBiologics Appoints NASA Scientist Kate Rubins to Board
The latest update is out from FibroBiologics, Inc. ( ($FBLG) ). On July 2, 2026...
07-09 21:58
